Immunocore (IMCR) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Taysha Gene Therapies (TSHA) has outperformed Immunocore (IMCR) over the past year, losing 12.5% versus a loss of 14.4%. Over five years, IMCR leads with a -23.4% price change compared with -75.2% for TSHA. Immunocore is the larger company by market cap ($1.50 billion vs $1.44 billion), about 1.0 times the size.
Immunocore converts more of its revenue into profit, with a net margin of -8.9% versus -1115.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | TSHA |
|---|---|---|
| Share price | $29.09 | $4.43 |
| Market cap | $1.50B | $1.44B |
| 1-day change | -1.09% | 0.00% |
| YTD return | -16.19% | -19.45% |
| 1-year return | -14.42% | -12.45% |
| 5-year return | -23.45% | -75.22% |
| EPS (TTM) | $-0.36 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $400.02M | $9.77M |
| Revenue growth (YoY) | +28.95% | +17.28% |
| Net income (latest FY) | $-35.51M | $-109.00M |
| Gross margin | 98.73% | — |
| Operating margin | -11.34% | -1130.65% |
| Net margin | -8.88% | -1115.27% |
| 52-week high | $40.72 | $7.30 |
| 52-week low | $27.56 | $3.69 |
| Distance from 52-week high | -28.55% | -39.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +115.64% | +193.45% |
| Average volume | 443.48K | 3.28M |
| Shares outstanding | 51.50M | 325.83M |
| Employees | 524 | 99 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Immunocore is more profitable, keeping -8.9 cents of every revenue dollar as net income versus -1115.3 cents for Taysha Gene Therapies.
- Immunocore grew revenue faster in its latest fiscal year (+28.95% vs +17.28%).
- The two companies sit in different sectors: Immunocore in Health Care and Taysha Gene Therapies in Healthcare.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Healthcare · Biotechnology · 99 employees
IMCR vs TSHA FAQ
Which is bigger, Immunocore or Taysha Gene Therapies?
Immunocore (IMCR) is larger, with a market capitalization of $1.50B compared with $1.44B for Taysha Gene Therapies (TSHA).
Which stock has performed better over the past year, IMCR or TSHA?
TSHA returned -12.45% over the past 12 months, compared with -14.42% for IMCR (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Taysha Gene Therapies in the same industry?
No. Immunocore is in the Health Care sector, while Taysha Gene Therapies is in Healthcare.